Angiogenesis in primary lung cancer and lung secondaries

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2494-2500

  Pezzella, F ^a,b   Di Bacco, A D ^b   Andreola, S ^c   Nicholson, A G ^d   Pastorino, U ^d   Harris, A L ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BREAST CARCINOMA; CLINICAL ARTICLE; COLON CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LUNG CANCER; LUNG METASTASIS; MELANOMA; PRIORITY JOURNAL; REVIEW;

EID: 0030498145     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00377-2     Document Type: Article

References (34)

1. 1. McVie JG. Cancer of lung and pleura. In Hossfeld DK, Sherman CD, Love PR, Bosch FX, eds. UICC Manual of Clinical Oncology. Berlin, UICC, Springer Verlag, 1990, 217-227.
2. 2. Ginsberg RJ, Kris MG, Armstrong JG. Non-small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott Co., 1993, 673-723.
3. 3. Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott Co., 1993, 723-758.
4. 4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995, 1, 27-31.
5. 5. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995, 147, 9-19.
6. 6. Ito T, Kitamura H, Nakamura N, Kameda Y, Kanisawa M. A comparative study of vascular proliferation in brain metastasis of lung carcinomas. Virchows Arch A Pathol Anat 1993, 423, 13-17.
7. 7. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995, 177, 57-63.
8. 8. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Angiogenesis is a significant prognostic marker in operable non small cell lung cancer. J Pathol 1995, 179, 80-88.
9. 9. Yamazaki K, Abe S, Takekawa H, et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer 1994, 74, 2245-2250.
10. 10. Yuan A, Yng PC, Yu CJ, et al. Tumour angiogenesis correlates with histologic type and metastasis in non-small cell lung cancer. Am J Resp Crit Care Med 1995, 152(6 Pt 1), 2157-2162.
11. 11. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non small cell lung cancer. Lancet 1992, 340, 145-146.
12. 12. Macchiarini P, Fontanini G, Dulmet E, et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994, 57, 1534-1539.
13. 13. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995, 1, 149-153.
14. 14. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Kosmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348, 334-336.
15. 15. Yonis-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimichi A, Oren M. Wild type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991, 352, 345-347.
16. 16. Mason DY, Abdulaziz ZA, Falini B, Stein H. Single and double immunostaining technique for labelling tissue sections with monoclonal antibodies. Ann NY Acad Sci 1984, 420, 127-133.
17. 17. Parmus DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990, 43, 752-757.
18. 18. Pezzella F, Tse A, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 protein is not specific for the 14;18 chromosomal translocation. Am J Path 1990, 137, 225-232.
19. 19. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GNA, Harris AL. Quantification of angjogenesis as an independent predictor of prognosis in invasive bladder carcinoma. Br J Urol 1994, 74, 762-766.
20. 20. Murray C. Tumour dormancy: not so sleepy after all. Nature Medicine 1995, 1, 117-118.
21. 21. Cassels R, Fears R, Smith RA. The interaction of streptokinase plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen, Relationship to fibrinolytic potency in vitro. Biochem J 1987, 247, 395-400.
22. 22. Brown PD, Bloxidge RA, Stuart NSA, Gatter KC, Carmichael J. Correlation between expression of activated 72 kDa gelatinase and tumour spread in non-small cell lung carcinoma. J Natl Cancer Inst 1993, 85, 574-578.
23. 23. McDonnel S, Navre M, Coffeuy RJ, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinoma. Mol Carcinogenesis 1991, 4, 527-533.
24. 24. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genetics 1990, 6, 121-125.
25. 25. Pezzella F, Micklem K, Turley H, et al. An antibody which detects by immunohistochemistry the presence of P53 protein in normal human tissues. J Clin Pathol 1994, 47, 592-596.
26. 26. Harris AL. What does Bcl-2 mean in solid tumours - friend or foe? Ann Oncol 1994, 5, 388-390.
27. 27. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma. Association with ER positive EGFR negative tumours and in situ cancer. Br J Cancer 1994, 69, 135-139.
28. 28. Doglioni C, Dei Tos AP, Laurino L, Moschini A, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to the oestrogen receptor status. Virchow Arch 1994, 424, 47-51.
29. 29. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am J Pathol 1994, 145, 1191-1198.
30. 30. Nathan B, Gusterson B, Jadayel D, et al. Expression of bcl-2 in primary breast cancer and its correlation with tumour phenotype. Annal Oncol 1994, 5, 409-414.
31. 31. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994, 86, 499-504.
32. 32. Hellmans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995, 72, 354-360.
33. 33. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 fraction. Virchow Arch 1995, 426, 229-233.
34. 34. Travis WD, Travis LB, Devesea SS. Lung cancer. Cancer 1995, 75, 191-202.